Madeline Elizabeth DeWane, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatology | 5 | 2020 | 914 | 1.370 |
Why?
|
| Dermatomyositis | 3 | 2020 | 256 | 1.220 |
Why?
|
| Ethics, Medical | 2 | 2019 | 787 | 0.880 |
Why?
|
| Blister | 1 | 2023 | 87 | 0.840 |
Why?
|
| Chickenpox | 1 | 2022 | 98 | 0.770 |
Why?
|
| Pancytopenia | 1 | 2022 | 101 | 0.760 |
Why?
|
| Professional Corporations | 1 | 2020 | 9 | 0.710 |
Why?
|
| Job Application | 1 | 2019 | 38 | 0.690 |
Why?
|
| Herpes Zoster | 1 | 2022 | 251 | 0.670 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2019 | 25 | 0.660 |
Why?
|
| Private Practice | 1 | 2020 | 153 | 0.650 |
Why?
|
| Sexual Harassment | 1 | 2019 | 80 | 0.620 |
Why?
|
| Leg | 1 | 2023 | 1091 | 0.600 |
Why?
|
| Sunlight | 1 | 2019 | 337 | 0.570 |
Why?
|
| Diabetes Complications | 1 | 2023 | 1342 | 0.520 |
Why?
|
| Autoantigens | 2 | 2019 | 877 | 0.520 |
Why?
|
| Confidentiality | 1 | 2019 | 610 | 0.480 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2019 | 907 | 0.450 |
Why?
|
| Truth Disclosure | 1 | 2018 | 432 | 0.450 |
Why?
|
| Autoantibodies | 2 | 2019 | 2119 | 0.450 |
Why?
|
| Facial Dermatoses | 2 | 2020 | 85 | 0.330 |
Why?
|
| Skin | 3 | 2019 | 4468 | 0.330 |
Why?
|
| Internship and Residency | 2 | 2019 | 5867 | 0.330 |
Why?
|
| Erythema | 2 | 2020 | 262 | 0.310 |
Why?
|
| Dermatitis, Atopic | 3 | 2019 | 710 | 0.230 |
Why?
|
| Diet | 1 | 2021 | 8008 | 0.220 |
Why?
|
| Melanoma | 1 | 2021 | 5695 | 0.210 |
Why?
|
| Herpesvirus 3, Human | 1 | 2022 | 159 | 0.190 |
Why?
|
| Physicians | 1 | 2019 | 4590 | 0.180 |
Why?
|
| Eczema, Dyshidrotic | 1 | 2020 | 1 | 0.180 |
Why?
|
| Drug Eruptions | 2 | 2020 | 335 | 0.170 |
Why?
|
| Foot Dermatoses | 1 | 2020 | 47 | 0.170 |
Why?
|
| Hand Dermatoses | 1 | 2020 | 62 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5797 | 0.170 |
Why?
|
| Biopsy | 3 | 2019 | 6775 | 0.160 |
Why?
|
| Dermoscopy | 1 | 2019 | 66 | 0.160 |
Why?
|
| Conjunctivitis | 1 | 2019 | 155 | 0.150 |
Why?
|
| Paternalism | 1 | 2018 | 47 | 0.150 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 190 | 0.150 |
Why?
|
| Skin Aging | 1 | 2019 | 141 | 0.150 |
Why?
|
| Sutures | 1 | 2019 | 294 | 0.150 |
Why?
|
| Eczema | 1 | 2019 | 245 | 0.140 |
Why?
|
| Personal Autonomy | 1 | 2018 | 302 | 0.130 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 306 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 729 | 0.120 |
Why?
|
| Exanthema | 1 | 2019 | 504 | 0.120 |
Why?
|
| Patient Care | 1 | 2020 | 624 | 0.120 |
Why?
|
| Culture | 1 | 2018 | 622 | 0.110 |
Why?
|
| Eye Diseases | 1 | 2019 | 651 | 0.110 |
Why?
|
| Causality | 1 | 2020 | 1241 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1790 | 0.110 |
Why?
|
| Neoplasms | 2 | 2019 | 22066 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2019 | 4637 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 1972 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 989 | 0.110 |
Why?
|
| Humans | 18 | 2023 | 760261 | 0.100 |
Why?
|
| Patient Preference | 1 | 2019 | 921 | 0.100 |
Why?
|
| Biocompatible Materials | 1 | 2019 | 1689 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3618 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 21065 | 0.090 |
Why?
|
| Patient Participation | 1 | 2018 | 1437 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 4923 | 0.070 |
Why?
|
| Students, Medical | 1 | 2019 | 1926 | 0.060 |
Why?
|
| Developing Countries | 1 | 2018 | 2880 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5884 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12968 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 10340 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5324 | 0.050 |
Why?
|
| Adult | 6 | 2020 | 219847 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5396 | 0.040 |
Why?
|
| Young Adult | 3 | 2019 | 58673 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2020 | 64947 | 0.040 |
Why?
|
| Child | 3 | 2020 | 79758 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2019 | 299 | 0.030 |
Why?
|
| Female | 6 | 2020 | 391011 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2019 | 1133 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 74269 | 0.030 |
Why?
|
| Male | 5 | 2020 | 359413 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 15827 | 0.020 |
Why?
|
| United States | 1 | 2019 | 72363 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2020 | 80301 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 87747 | 0.020 |
Why?
|
| Aged | 3 | 2020 | 168995 | 0.010 |
Why?
|
| Middle Aged | 3 | 2020 | 220175 | 0.010 |
Why?
|
| Inflammation | 1 | 2019 | 10757 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 167940 | 0.000 |
Why?
|